Lifestyle Medicine and Medication Safety in Viet Nam: Deprescribing, Dose Adjustment and When Lifestyle Change Alters Treatment Needs
EVIDENCE & CLINICAL PRACTICELIFESTYLE MEDICINE IN VIET NAM


Lifestyle Medicine and Medication Safety in Viet Nam: Deprescribing, Dose Adjustment and When Lifestyle Change Alters Treatment Needs
Last reviewed: November 7, 2026
Lifestyle Medicine is sometimes presented as a way to reduce dependence on medication. In some circumstances, that may be possible. Meaningful changes in nutrition, physical activity, body weight and other health behaviors can improve blood glucose, blood pressure and several other clinical outcomes.
But there is an important question that deserves more attention: What happens when a treatment that was appropriate before those changes is no longer the safest or most appropriate treatment for the patient?
Consider someone with type 2 diabetes who begins a substantial dietary intervention while continuing to take insulin or another medication that can cause hypoglycemia. Their glucose levels may improve, but without appropriate monitoring and treatment review, the risk of low blood glucose may increase.
A similar situation can occur in hypertension. A patient who loses weight, reduces sodium intake and becomes more physically active may experience lower blood pressure. That can be beneficial, but some patients may develop dizziness, weakness or symptomatic hypotension while continuing their existing medication regimen.
The opposite problem is equally important. A patient may decide to stop medication after seeing a few improved readings, even though treatment remains necessary to prevent complications or provide cardiovascular or kidney protection.
Neither situation represents good medication management.
The purpose of Lifestyle Medicine should not be to help everyone stop taking medication. It should be to improve health through evidence-based interventions while ensuring that all treatments remain appropriate as the patient's condition changes.
Medication safety is therefore not separate from Lifestyle Medicine. It is an essential part of responsible clinical care.
Deprescribing Is a Clinical Process, Not an Anti-Medication Approach
Deprescribing refers to a planned and supervised process of reducing, discontinuing or replacing medication when its expected benefits, risks or clinical indications have changed.
It is different from simply advising a patient to stop taking a drug.
A medication may have been entirely appropriate when it was prescribed. Over time, the patient's disease status, treatment response, other medical conditions or personal circumstances may change. A review may then establish that a lower dose, a different medicine or discontinuation is appropriate.
In other cases, continuing treatment remains the safest decision.
The 2025 American College of Lifestyle Medicine clinical practice guideline on type 2 diabetes and prediabetes addresses this directly. Its recommendation on adjusting pharmacological therapy recognizes that effective lifestyle interventions may change medication requirements and that treatment should be reviewed accordingly.
This is part of good prescribing practice rather than an argument against medication.
The same principle applies outside diabetes care. A medication should be continued when its expected benefits remain appropriate, modified when the balance of benefit and harm changes, and discontinued only when a clinically justified decision has been made.
The goal is not the lowest possible number of medications.
It is to ensure that every medication remains necessary, effective and safe for the patient's current condition.
Why Lifestyle Change Can Alter Medication Requirements
Lifestyle interventions may affect some of the same physiological processes targeted by medication.
Changes in dietary intake, physical activity, body weight and alcohol consumption can influence glucose regulation, blood pressure and other metabolic parameters. Smoking cessation can also change the metabolism of certain medicines.
The extent and timing of these effects vary.
Some changes develop gradually and can be reviewed during routine appointments. Others may occur relatively quickly, particularly when patients make substantial changes in energy intake, carbohydrate consumption or physical activity while taking medications with a higher risk of adverse effects.
The clinical challenge is anticipating these changes rather than waiting until a patient experiences harm.
Before recommending an intensive lifestyle intervention, healthcare professionals need to understand what medications the person is taking, why they were prescribed and whether the intervention could change their effects or safety.
A medication review is particularly important when the treatment regimen includes drugs associated with hypoglycemia, hypotension, dehydration, electrolyte disturbances or other clinically significant risks.
A successful lifestyle intervention should improve care, not introduce avoidable medication-related complications.
Type 2 Diabetes: When Better Glucose Control Creates a Safety Concern
Type 2 diabetes provides one of the clearest examples of why medication review must accompany substantial lifestyle change.
The American Diabetes Association's Standards of Care in Diabetes 2026 emphasize individualized treatment, periodic reassessment and reducing treatment intensity when the risks or burdens of treatment outweigh its benefits.
The recommendations identify insulin, sulfonylureas and meglitinides as medication groups with particularly important hypoglycemia risks.
These medicines can lower glucose effectively, but their use requires attention when a patient's dietary intake, physical activity or glucose control changes.
Someone taking insulin who substantially reduces food intake may require earlier glucose monitoring and medical review. Similarly, a patient receiving a sulfonylurea may become more vulnerable to hypoglycemia when glucose regulation improves or meals become irregular.
This does not mean that these medications should automatically be stopped when a patient adopts a healthier lifestyle.
It means that the clinician responsible for treatment should anticipate possible changes in medication requirements and establish a safe monitoring plan.
The American College of Lifestyle Medicine's 2025 guideline emphasizes proactive medication review in patients undertaking substantial therapeutic lifestyle interventions, particularly where treatment could increase hypoglycemia risk.
Its recommendations include ongoing assessment, individualized planning, patient education, appropriate glucose monitoring and communication among members of the healthcare team.
For selected patients, reducing the intensity of glucose-lowering treatment may be appropriate. For others, maintaining treatment remains necessary.
An important distinction is that different diabetes medications have different risk profiles and indications.
Metformin, when used alone, generally carries a low risk of hypoglycemia. Some newer glucose-lowering medications also provide benefits beyond glucose control.
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists may be indicated for particular patients because of cardiovascular disease, heart failure, chronic kidney disease, weight-related needs or other relevant clinical considerations.
Consequently, improvement in glycated hemoglobin does not automatically mean that these medications should be withdrawn.
The clinician must review the reason each medication was prescribed, the benefits it continues to provide and the risks associated with changing it.
For people with type 1 diabetes, insulin is essential treatment and must not be discontinued simply because dietary habits or glucose measurements improve.
The distinction between improved disease control and reduced medication requirements is fundamental to safe diabetes care.
Intensive Dietary Changes Require Additional Attention
Not every dietary intervention carries the same medication-related risks.
A gradual improvement in dietary quality may have different implications from a substantial reduction in carbohydrate intake, prolonged fasting or a highly restrictive weight-loss program.
The intensity of the intervention, the patient's medical conditions and the medications involved all influence the appropriate monitoring plan.
For patients receiving insulin or other glucose-lowering medicines associated with hypoglycemia, major changes in dietary intake may require more frequent glucose monitoring and timely review by the treating clinician.
There is also a separate safety issue involving sodium-glucose cotransporter-2 inhibitors.
The American Diabetes Association's 2026 Standards identify very-low-carbohydrate eating patterns, prolonged fasting, dehydration and excessive alcohol intake among factors associated with diabetic ketoacidosis in people using these medications.
Diabetic ketoacidosis is uncommon in people with type 2 diabetes taking these drugs, but it can occur. Importantly, blood glucose may not be markedly elevated in every case.
This creates a risk when symptoms are overlooked because a patient or clinician assumes that relatively normal glucose readings exclude a serious metabolic problem.
The appropriate response is not to discourage every patient from using these medications or undertaking dietary changes.
It is to ensure that significant dietary interventions are reviewed in the context of the person's treatment regimen and clinical risks.
Patients should receive appropriate education about relevant warning symptoms, including circumstances requiring urgent medical assessment.
They should not independently stop, reduce or substitute prescribed medicines when planning a restrictive diet or fasting regimen. Any medication plan for these situations must be established by an appropriately authorized prescriber.
Blood Pressure May Improve, but Treatment Still Needs Review
Lifestyle interventions are central to the prevention and management of hypertension.
The 2025 American Heart Association and American College of Cardiology hypertension guideline emphasizes weight management where appropriate, healthy dietary patterns, sodium reduction, physical activity, stress management and reducing alcohol consumption.
These interventions can improve blood pressure and contribute to long-term cardiovascular health.
For some patients, meaningful improvements may change medication requirements.
However, a patient receiving antihypertensive treatment can develop symptomatic hypotension if the overall blood-pressure-lowering effect becomes excessive.
Potential symptoms include dizziness, weakness, lightheadedness, faintness and difficulties associated with standing.
The risk depends on the patient's clinical condition, age, hydration, medication regimen and other factors.
Particular attention may be needed for patients taking diuretics, because changes in hydration or fluid balance can influence blood pressure and electrolyte status. Other antihypertensive medications may also contribute to symptomatic or orthostatic hypotension, especially when used in combination or in patients with increased vulnerability.
This is one reason reliable home blood-pressure monitoring can be valuable when substantial lifestyle interventions are introduced.
Monitoring should use an appropriate validated device and measurement technique. Readings must be interpreted in the context of symptoms, clinical history and relevant treatment goals.
A single improved blood-pressure reading is not sufficient evidence that medication should be reduced or stopped.
Some medications used to lower blood pressure are also prescribed for heart failure, chronic kidney disease, coronary disease or other conditions.
Their benefits may continue even when blood pressure has improved.
The treatment decision must therefore consider the complete clinical indication rather than one measurement.
Patients should not stop or adjust blood-pressure medication on their own because home readings have improved.
When persistent low readings, dizziness, falls or other concerning symptoms occur, the patient should contact the responsible healthcare professional for reassessment.
Severe symptoms such as fainting accompanied by injury, chest pain, marked breathlessness or signs of acute neurological impairment require urgent medical evaluation rather than routine follow-up.
Medication Safety Extends Beyond Diabetes and Hypertension
Lifestyle changes can affect other medications through mechanisms that are not directly related to glucose control or blood pressure.
Smoking cessation provides an important example.
Components of tobacco smoke can increase the activity of liver enzymes involved in metabolizing certain medicines. When smoking is reduced or stopped, the metabolism of some drugs may change, leading to higher drug concentrations and a greater risk of adverse effects.
This interaction is primarily related to substances in tobacco smoke rather than nicotine itself.
Clozapine is a clinically important example. Changes in smoking status can significantly affect drug exposure, and dose adjustment or additional monitoring may be necessary under specialist supervision.
The lesson is not to discourage smoking cessation. Smoking cessation remains an important health intervention.
Rather, healthcare professionals should anticipate medication interactions and coordinate appropriate monitoring when relevant.
Dietary changes can also affect anticoagulant therapy.
People taking warfarin do not generally need to avoid vegetables containing vitamin K. However, substantial or unpredictable changes in vitamin K intake can influence anticoagulation control.
A major dietary change may therefore require additional counseling and monitoring of the International Normalized Ratio.
Maintaining a reasonably consistent intake is generally more appropriate than unnecessarily eliminating nutritious foods.
Kidney disease presents another situation requiring individualized advice.
Dietary potassium and potassium-containing salt substitutes can have important implications for people with impaired potassium excretion or those taking certain medicines affecting the renin-angiotensin-aldosterone system.
The Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline emphasizes individualized management of potassium-related risks while recognizing the continuing benefits of indicated kidney-protective therapies.
These examples illustrate a broader principle.
A lifestyle intervention can change medication safety even when the medicine was prescribed for a condition that is not usually described as lifestyle-related.
When Reducing Medication May Be the Wrong Decision
Reducing medication is not always evidence of better care.
A patient may experience improved blood glucose, blood pressure or cholesterol while still having an important indication for preventive or disease-modifying treatment.
For example, some medications provide cardiovascular or kidney protection beyond their effects on a single laboratory result.
Other medications may be essential for preventing serious complications or controlling conditions that remain active despite improvements in lifestyle.
Certain drugs also require gradual reduction or specialist supervision because abrupt withdrawal can produce clinically significant harm.
Decisions about discontinuing these therapies must consider the underlying disease, the medication's indication, the risks of withdrawal and available alternatives.
Even remission of type 2 diabetes should not be equated with permanent cure.
People who achieve remission may still require ongoing surveillance, assessment of complications and management of cardiovascular or kidney risk.
The same principle applies to hypertension. Improvement in blood pressure does not establish that future cardiovascular risk has disappeared.
For these reasons, the number of medications a patient takes is a poor measure of whether a Lifestyle Medicine intervention has succeeded.
More meaningful outcomes include improved health and function, avoidance of preventable adverse events, appropriate disease control and reduction of unnecessary treatment burden.
Sometimes achieving those outcomes involves fewer medicines.
Sometimes it involves continuing them.
Reassessment Should Be Planned Before Lifestyle Treatment Begins
One of the most important improvements healthcare organizations can make is to define medication-review responsibilities and follow-up arrangements before a substantial lifestyle intervention starts.
The plan should reflect the individual patient's risk rather than a universal schedule.
Before the intervention begins, the treating clinician should review relevant diagnoses, current medications, indications, previous adverse effects and baseline clinical information. The team should identify which medicines may require closer monitoring if the intervention produces a significant physiological response.
For patients with diabetes, this may involve existing glucose measurements, glycated hemoglobin, hypoglycemia history and relevant treatment information. For patients with hypertension, baseline blood pressure, symptoms, medication use and relevant kidney or electrolyte results may be important.
The clinician should also determine how the patient will monitor relevant parameters and what findings should trigger earlier contact.
During the first days and weeks, closer monitoring may be needed when intensive dietary changes, major changes in physical activity or other interventions could rapidly affect medication requirements.
For people taking insulin or sulfonylureas, waiting several months for the next glycated hemoglobin measurement may be inadequate if glucose levels are changing substantially. Self-monitoring of blood glucose or continuous glucose monitoring, where appropriate and available, can support more timely clinical decisions.
The American College of Lifestyle Medicine's diabetes guideline includes intensive early glucose monitoring considerations for selected patients undergoing substantial dietary interventions, particularly during the first two weeks.
The monitoring frequency must still be individualized according to medication type, hypoglycemia risk, available resources and the treating clinician's plan.
For patients receiving blood-pressure medication, home measurements may help identify meaningful changes. A review within the early weeks may be appropriate when an intervention is substantial or symptoms develop, with earlier assessment whenever clinically necessary.
The 2025 American Heart Association and American College of Cardiology guideline recommends monthly follow-up for adults with uncontrolled hypertension receiving newly initiated or intensified antihypertensive treatment until control is achieved.
That recommendation concerns a specific clinical situation and should not be interpreted as a universal Lifestyle Medicine follow-up interval.
At approximately three months, glycated hemoglobin is often useful for assessing the broader effect of changes in diabetes treatment. The American Diabetes Association's 2026 Standards recommend assessing glycemic status more frequently, for example every three months, when treatment has changed, glucose targets are not being achieved or clinically significant glucose abnormalities occur.
Patients with stable, well-controlled diabetes may require less frequent glycated hemoglobin measurement, commonly at least twice yearly, depending on individual circumstances.
These longer-term assessments do not replace early glucose monitoring when there is a risk of hypoglycemia or rapid treatment-related changes.
After any medication adjustment, the clinician should establish the next monitoring and review arrangements. The interval should reflect the medication, the patient's clinical condition and the potential consequences of the change.
There is no single evidence-based deprescribing timetable suitable for all medications or all Lifestyle Medicine interventions.
A useful follow-up plan therefore identifies the expected response, the relevant monitoring method, the responsible reviewer and the circumstances requiring earlier reassessment.
The timing should be clinically justified rather than determined solely by the duration of the original prescription.
Patients Need Clear Instructions About When to Seek Help
A medication-safety plan is incomplete if the patient does not understand what to do when symptoms or measurements change.
Healthcare professionals should explain which findings are expected, which require discussion with the treating team and which require urgent assessment.
For people receiving diabetes medication, repeated low glucose readings, symptoms consistent with hypoglycemia or unexpected changes in glucose control should prompt appropriate review.
Severe hypoglycemia involving confusion, seizures, loss of consciousness or a need for assistance is a medical emergency.
For people receiving antihypertensive treatment, persistent dizziness, symptomatic low blood pressure, fainting or falls may indicate a need for clinical reassessment.
Other symptoms should be evaluated according to the medication and condition involved.
For example, unusual bleeding may be particularly important for patients receiving anticoagulants, while symptoms suggesting severe metabolic deterioration require urgent evaluation in patients at risk of diabetic ketoacidosis.
Patients should know how to contact the appropriate healthcare service and what to do when the prescribing clinician is unavailable.
They should also understand that improved measurements do not necessarily mean treatment is no longer needed.
Patients should never independently stop, reduce, increase, replace or otherwise alter prescribed medication simply because a lifestyle intervention appears to be working.
Where an emergency occurs, patients should receive timely medical care according to established emergency procedures rather than wait for a scheduled medication-review appointment.
What Does Vietnamese Law Require?
Medication adjustment in Viet Nam must be undertaken within the legal and professional framework governing medical examination, treatment and prescribing.
The Law on Medical Examination and Treatment, currently reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026, establishes the general responsibilities of healthcare practitioners and facilities.
Article 62 addresses professional responsibilities in medical examination and treatment, including appropriate diagnosis, treatment decisions and prescribing.
Article 63 establishes principles for the safe, rational and effective use of medicines. These include prescribing medicines when necessary, ensuring that treatment is appropriate to the diagnosis and clinical condition, and documenting relevant medication information.
For outpatient prescribing of chemical medicines and biological products, Circular No. 26/2025/TT-BYT, issued by the Ministry of Health on June 30, 2025 and effective July 1, 2025, provides more specific requirements.
Article 2 identifies prescribing authority for healthcare practitioners holding a valid practice certificate or practice license with the recognized professional title of bác sĩ or y sĩ.
The specific prescribing activity must remain consistent with applicable professional scope, licensing conditions and other relevant legal requirements.
The Circular also addresses the requirements for outpatient prescriptions and the responsibilities of prescribers.
Under Article 6, Clause 9, when medication in an outpatient prescription needs to be corrected or adjusted, the prescriber must issue a new prescription replacing the previous one.
This is particularly relevant when a lifestyle intervention leads to a clinically indicated change in prescribed treatment.
The legal responsibility for prescribing does not transfer to a nutrition professional, health coach, exercise specialist or other member of the care team merely because that person is delivering a Lifestyle Medicine intervention.
Such professionals may identify concerns, support monitoring and communicate relevant clinical information according to their roles. However, a decision to change prescribed medication must be made by a practitioner who has the required legal authority and professional scope.
International Lifestyle Medicine education or certification does not independently grant prescribing authority in Viet Nam.
This distinction should be clearly understood by both healthcare organizations and patients.
A 90-Day Prescription Does Not Mean Waiting 90 Days for Review
Circular No. 26/2025/TT-BYT also allows extended outpatient prescriptions for specified diseases and disease groups listed in its Appendix VII.
Where the applicable conditions are met, the prescriber may determine a medication duration exceeding 30 days, up to a maximum of 90 days, based on the patient's clinical status and stability.
This provision can support continuity of treatment for people with stable chronic conditions and reduce unnecessary administrative burden.
However, the authorized prescription duration should not be confused with the clinically appropriate interval for reassessment.
A patient who receives a 90-day prescription may still require review much earlier if symptoms, monitoring results or treatment circumstances change.
For example, someone beginning a substantial dietary intervention while receiving medication associated with hypoglycemia should not automatically wait until the end of the prescription period for reassessment.
The same applies to patients who develop symptomatic hypotension or other medication-related concerns.
The treating clinician remains responsible for establishing appropriate follow-up and responding to clinically significant changes.
The most appropriate monitoring interval depends on risk and treatment needs, not simply how much medication has been dispensed.
The Role of Clinical Pharmacists and Multidisciplinary Teams
Medication review is particularly important when patients have multiple chronic conditions, take several medicines or receive treatment from different specialists.
In these situations, changes recommended by one professional may affect treatments prescribed by another.
Clinical pharmacists can make an important contribution to medication safety.
Decree No. 131/2020/NĐ-CP, effective January 1, 2021, provides the Vietnamese regulatory framework for clinical pharmacy activities in medical examination and treatment facilities.
These activities include supporting the appropriate selection and use of medicines, reviewing indications, doses, interactions and contraindications, monitoring medication-related problems and providing professional advice in coordination with the healthcare team.
For Lifestyle Medicine programs, clinical pharmacy input can be especially valuable when patients have polypharmacy, kidney impairment, complex medication regimens or an increased risk of adverse effects.
Nurses may support relevant monitoring, education, identification of concerning findings and communication with the treating clinician within their authorized roles.
Clinical nutrition professionals may identify significant dietary changes that could affect medication safety and communicate those changes to the appropriate prescriber.
Other professionals involved in physical activity, rehabilitation or behavior-change support may also recognize concerns that require medical review.
The objective is not to make every team member responsible for prescribing.
It is to ensure that clinically important information reaches the practitioner authorized to make treatment decisions.
Where several specialists are involved, the organization should establish a clear process for communicating medication changes and resolving potentially conflicting instructions.
A patient should not be left to decide which of two different medication plans to follow.
What Should Healthcare Organizations Build Into Their Care Pathways?
A Lifestyle Medicine program should not depend on informal communication to manage medication-related risks.
Medication review, monitoring and escalation should be incorporated into the clinical pathway from the beginning.
Before a substantial intervention is undertaken, the care team should know what medicines the patient uses, which conditions they treat and which medications require additional attention.
The plan should identify how relevant clinical information will be monitored, who will review it, how patients can report concerns and who has authority to change treatment.
When treatment is adjusted, the rationale and new prescription should be documented and communicated to the relevant healthcare professionals.
The patient should receive clear instructions about the updated regimen, and follow-up should confirm whether the change achieved the intended outcome without creating new problems.
The organization should also consider how its systems identify and respond to missed follow-up appointments, recurrent hypoglycemia, symptomatic hypotension or other medication-related incidents.
Electronic health records may support communication when information about medication, lifestyle interventions, clinical monitoring and follow-up is accessible to authorized members of the care team.
However, technology cannot replace clear professional accountability.
Organizations can also use quality-improvement methods to examine whether medication review occurs before intensive lifestyle intervention, whether high-risk patients receive appropriate monitoring, whether treatment adjustments are documented and whether medication-related safety concerns are recognized promptly.
These measures provide a more meaningful assessment of medication safety than simply counting how many prescriptions have been reduced.
Evidence on Deprescribing After Lifestyle Change Is Still Developing
Although there is growing recognition that successful lifestyle interventions may change medication requirements, the evidence supporting specific deprescribing sequences and schedules remains incomplete.
A cross-sectional study published online in March 2026 examined medication deprescribing practices among Lifestyle Medicine clinicians involved in treatment decisions.
The study included 67 respondents. Approximately 53% reported that they did not use an established protocol for deprescribing diabetes medications.
Clinicians commonly described individualized approaches based on glucose monitoring and patient response. Medications associated with hypoglycemia, including sulfonylureas and mealtime insulin, were frequently considered for adjustment.
These findings are informative but should not be interpreted as establishing a universal clinical standard.
The survey involved a relatively small, selected group of clinicians and reported their practices rather than demonstrating the comparative safety or effectiveness of different deprescribing strategies.
It nevertheless highlights an important implementation challenge.
Healthcare professionals recognize the need to adjust treatment, but standardized approaches are still evolving.
Organizations should therefore use relevant disease-specific guidelines, established medication-safety principles and clinical judgment rather than adopt a single deprescribing algorithm for every patient.
Local evaluation is also needed to understand what can be implemented safely and consistently in Vietnamese healthcare settings.
What Patients Should Understand
For patients, the central message is straightforward.
Healthy lifestyle changes can improve clinical outcomes and may alter medication needs, but this does not mean that medication should be changed without professional assessment.
People taking medication for diabetes, hypertension, cardiovascular disease, kidney disease or other chronic conditions should inform their treating healthcare professionals before undertaking major changes in diet, fasting practices, physical activity or weight-loss programs when those changes could affect treatment.
They should also report significant changes in smoking status where relevant medication interactions may occur.
Home glucose and blood-pressure measurements can provide valuable information, but they need to be interpreted within an appropriate clinical plan.
Patients should not use a few improved readings as the sole reason to discontinue treatment.
They should also know which symptoms require earlier contact and which situations require urgent medical attention.
Medication changes should be discussed through shared decision-making, with clear explanations of the potential benefits, risks, alternatives and monitoring requirements.
The patient has an important role in reporting symptoms, following agreed monitoring plans and communicating changes in health behaviors.
The authorized prescriber remains responsible for the clinical decision to change medication.
The Better Question Is Not Whether Medication Can Be Stopped
There is a difference between reducing unnecessary medication and treating medication reduction as a goal in itself.
Sometimes meaningful lifestyle improvement will make a lower dose appropriate. Sometimes a particular medication may no longer be required. In other situations, changing treatment may create greater risk than continuing it.
A medication may still be protecting the heart or kidneys even when a particular clinical measurement has improved.
For people with chronic disease, the most useful question is therefore not simply, “Can I stop taking this medication?”
It is, “Now that my health is changing, is my current treatment still the safest and most appropriate treatment for me?”
That question places medication decisions within the wider clinical context.
For Lifestyle Medicine in Viet Nam, this is an important distinction.
The field should not promise freedom from medication or suggest that pharmacological treatment represents failure.
Its contribution is to support evidence-based improvements in health while helping healthcare professionals recognize when treatment requirements may have changed.
The practical responsibility is to connect lifestyle interventions with medication review, timely monitoring, patient education and decisions made by appropriately qualified and authorized prescribers.
The success of Lifestyle Medicine should not be measured by how many medications a patient stops taking. It should be measured by whether the person receives safer, more effective and more appropriate care as their health changes.
References
Rea BL, Cheema S, Lanza S, et al. Lifestyle Medicine Core Competencies: 2025 Update. American Journal of Lifestyle Medicine. 2026;20(3):443–451. First published online October 28, 2025. doi:10.1177/15598276251379821.
Rosenfeld RM, Grega ML, Karlsen MC, et al. Lifestyle Interventions for Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults: A Clinical Practice Guideline From the American College of Lifestyle Medicine. American Journal of Lifestyle Medicine. 2025;19(2 Suppl):10S–131S. doi:10.1177/15598276251325488.
Macfield J, Staffier KL, Kelly J, Moghe R, Karlsen MC. Medication Deprescribing Practices Among Lifestyle Medicine Providers: A Cross-Sectional Survey. American Journal of Lifestyle Medicine. Published online March 27, 2026. doi:10.1177/15598276261430281.
American Diabetes Association Professional Practice Committee for Diabetes. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes, 2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-S006.
American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes, 2026. Diabetes Care. 2026;49(Suppl 1)–S215. doi:10.2337/dc26-S009.
Jones DW, Ferdinand KC, Taler SJ, et al. 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11). doi:10.1161/CIR.0000000000001356.
Kidney Disease: Improving Global Outcomes. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4 Suppl)–S314.
Office of the National Assembly of Viet Nam. Consolidated Document No. 26/VBHN-VPQH, Law on Medical Examination and Treatment. February 26, 2026.
Ministry of Health of Viet Nam. Circular No. 26/2025/TT-BYT on Prescriptions and Prescribing of Chemical Medicines and Biological Products in Outpatient Treatment at Medical Examination and Treatment Facilities. June 30, 2025. Effective July 1, 2025.
Government of Viet Nam. Decree No. 131/2020/NĐ-CP on the Organization and Activities of Clinical Pharmacy in Medical Examination and Treatment Facilities. November 2, 2020. Effective January 1, 2021.
NHS Specialist Pharmacy Service. Considering Drug Interactions With Smoking. Published October 31, 2023; updated November 8, 2023.
NHS Specialist Pharmacy Service. Managing Specific Interactions With Smoking. Published October 31, 2023.
National Health Service. Warfarin: Medicine Used to Prevent and Treat Blood Clots. Last reviewed February 24, 2026.
Educational and Clinical Governance Note
This article is intended for professional education, general information and discussion of medication safety in evidence-based Lifestyle Medicine. It does not constitute an individualized medication review, prescribing instruction, treatment protocol, deprescribing algorithm or authoritative legal opinion.
Patients should not independently stop, reduce, increase, replace or otherwise change prescribed medicines because of improvements in diet, physical activity, body weight, blood glucose, blood pressure or other health indicators.
Medication initiation, dose adjustment, reduction, substitution and discontinuation are clinical decisions that must be undertaken by appropriately qualified and legally authorized prescribing practitioners within their applicable scopes of practice and the requirements governing the healthcare facility.
The monitoring approaches and reassessment intervals discussed in this article are drawn from international clinical guidance and illustrative clinical considerations. They are not universal schedules or mandatory Vietnamese prescribing requirements. Individual care plans must account for the patient's condition, medication regimen, clinical risks and applicable Vietnamese regulations.
The Vietnam Lifestyle Medicine Alliance is a physician-led professional platform focused on evidence-based Lifestyle Medicine, professional education and scientific knowledge exchange. It is not a licensed medical examination or treatment facility and does not independently provide medical prescriptions, individualized medication adjustments or deprescribing services.
International scientific recommendations and clinical guidelines are referenced for educational purposes. They do not automatically establish professional authorization or regulatory requirements in Viet Nam.
Vietnam Lifestyle Medicine Alliance
Evidence-Based Lifestyle Medicine for Viet Nam.
Contact
contact@vlma.org
Saigon Paragon Building, No. 3 Nguyen Luong Bang Street, Tan My Ward, HCMC
+84 909 228 476
+84 84 9999 911
© 2025 - 2026. Vietnam Lifestyle Medicine Alliance. All rights reserved.
A physician-led professional platform advancing Lifestyle Medicine through education, collaboration, research, and responsible implementation.
VLMA is operated by Vietnam Lifestyle Medicine Alliance Company Limited, Enterprise Registration Number 0318902666.
VLMA is a Sister Organization of the Lifestyle Medicine Global Alliance and a Member Organization of the Planetary Health Alliance.
VLMA is not a medical service provider and does not issue medical licenses or IBLM certification.
